健康保险公司Financial Pulse 2023年第三季度上市公司

C O R P O R A T E P A R T I C I P A N T SBrian C. EvankoThe Cigna Group - Executive VP & CFODavid Michael CordaniThe Cigna Group - President, CEO & Chair of the BoardEric Paul PalmerEvernorth Health, Inc. - CEO, President & DirectorRalph GiacobbeThe Cigna Group - Senior VP & Head of IRC O N F E R E N C E C A L L P A R T I C I P A N T SAlbert J. William RiceUBS Investment Bank, Research Division - AnalystDavid Howard WindleyJefferies LLC, Research Division - MD & Equity AnalystGary Paul TaylorTD Cowen, Research Division - MD & Senior Equity Research AnalystJoshua Richard RaskinNephron Research LLC - Research AnalystJustin LakeWolfe Research, LLC - MD & Senior Healthcare Services AnalystKevin Mark FischbeckBofA Securities, Research Division - MD in Equity ResearchLance Arthur WilkesSanford C. Bernstein & Co., LLC., Research Division - Senior AnalystLisa Christine GillJPMorgan Chase & Co, Research Division - AnalystNathan Allen RichGoldman Sachs Group, Inc., Research Division - Research AnalystScott J. FidelStephens Inc., Research Division - MD & AnalystStephen C. BaxterWells Fargo Securities, LLC, Research Division - Senior Equity AnalystP R E S E N T A T I O NOperatorLadies and gentlemen, thank you for standing by for The Cigna Group's Third Quarter 2023 Results Review.(Operator Instructions) As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.We'll begin by turning the conference over to Ralph Giacobbe. Please go ahead.Ralph Giacobbe- The Cigna Group - Senior VP & Head of IRGreat. Thanks. Good morning, everyone. Thank you for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. Withme on the line this morning are David Cordani, The Cigna Group's Chairman and Chief Executive Officer; Brian Evanko, Chief Financial Officer; andEric Palmer, President and Chief Executive Officer of Evernorth Health Services.In our remarks today, David and Brian will cover a number of topics, including our third quarter financial results and our updated financial outlookfor 2023. Following their prepared remarks, David, Brian and Eric will be available for Q&A.As noted in our earnings release, when describing our financial results, we use certain financial measures including adjusted income from operationsand adjusted revenues, which are not determined in accordance with accounting principles generally accepted in the United States, otherwiseknown as GAAP.REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us©2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior writtenconsent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.NOVEMBER 02, 2023 / 12:30PM, CI.N - Q3 2023 The Cigna Group Earnings Call 2 A reconciliation of these measures to the most directly comparable GAAP measures, shareholders net income and total revenues, respectively, iscontained in today's earnings release, which is posted in the Investor Relations section of thecignagroup.com.We use the term labeled "adjusted income from operations" and "adjusted earnings per share" on the same basis as our principal measures offinancial performance.In our remarks today, we will be making some forward-looking statements, including statements regarding our outlook for 2023 and futureperformance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations.A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filedwith the SEC.Before turning over the call, I will cover a few items pertaining to our financial results.In the third quarter, we recorded an after-tax special item charge of $171 million or $0.58 per share for charges primarily associated with ourMedicare litigation settlement.We also recorded an after-tax special item charge of $19 million or $0.06 per share associated with the sale of our international life accidental andsupplemental business to Chubb, and an after-tax special item charge of $9 million or $0.03 per share for integration and transaction-related costs.As described in today's release, special items are excluded from adjusted income from operations and adjusted revenues in our discussion offinancial results.Additionally, please note that when we make prospective comments regarding financial performance, including our full year 2023 outlook, we willdo so on a basis that includes the potential impact of future share repurchases and anticipated 2023 dividends.With that, I'll turn the call over to David.David Michael Cordani- The Cigna Group - President, CEO & Chair of the BoardThanks, Ralph. Good morning, everyone, and thank you for joining today's call. We had another quarter of strong performance, and we remain onpace for a year of sust